Tempus AI

Tempus AI Stock-Based Compensation

The Stock-Based Compensation (SBC) of Tempus AI (TEM) as of Nov 20, 2026 is 124.75 M USD. In the previous year, Stock-Based Compensation (SBC) was 534.14 M USD — a change of -76.65% (lower).

Stock-Based Compensation

124.75 MUSD

YoY

-76.65%

Last updated:

Stock-Based Compensation (SBC) of Tempus AI is 2025 124.75 M USD. Stock-Based Compensation (SBC) of Tempus AI was 2024 534.14 M USD. It decreases by -76.65% lower compared to the previous year.

The Tempus AI Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
529,000.00 USD
Jan 1, 2020
399,000.00 USD
Jan 1, 2021
559,000.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
534.14 M USD
Jan 1, 2025
124.75 M USD
The Tempus AI Stock-Based Compensation history
YEARStock-Based CompensationYoY
124.75 MUSD-76.65%
534.14 MUSD—
0.00USD—
0.00USD-100.00%
559,000.00USD+40.10%
399,000.00USD-24.57%
529,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Stock-Based Compensation (SBC) of Tempus AI is 124.75 M USD in 2025.

Stock-Based Compensation (SBC) of Tempus AI changed from 534.14 M USD to 124.75 M USD, representing a -76.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tempus AI

All Key Metrics — Tempus AI